

Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma

Information for the public

Published: 1 March 2023

www.nice.org.uk

Polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) is available on the NHS. It is a possible treatment for untreated diffuse large B-cell lymphoma with an International Prognostic Index score of 2 to 5 in adults.

If you are not eligible for polatuzumab vedotin with R-CHP but already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

These organisations can give you advice and support:

- [Lymphoma Action](#), 0808 808 5555
- [Leukaemia Care](#), 08088 010 444
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5046-1